Charles River Laboratories International (CRL) Aktie Kurs

Charles River Laboratories International Inc is primarily active in the life sciences industry.

Some of the main competitors of Charles River Laboratories International Inc in the market include Covance Inc., Envigo, PPD, Eurofins Scientific, and LabCorp.

Charles River Laboratories International Inc is a renowned company in the field of preclinical and clinical laboratory services. Founded in 1947, Charles River has built a strong reputation as a trusted provider of comprehensive research support. With a focus on helping pharmaceutical and biotechnology companies bring new drugs to market, they offer a wide range of services including drug discovery, safety assessment, and manufacturing support to clients worldwide. The company's expertise in advanced animal models, laboratory sciences, and support services has propelled it to the forefront of the life sciences industry. Today, Charles River Laboratories continues to play a vital role in advancing much-needed medical therapies.

Charles River Laboratories International Inc has achieved several significant milestones. It has consistently demonstrated strong financial performance, delivering consistent revenue growth and expanding its global footprint. The company has successfully completed strategic acquisitions, enabling it to enhance its capabilities and expand its service offerings. Charles River Laboratories International Inc has also received notable recognition, including being named one of the World's Most Ethical Companies for several consecutive years. Moreover, the company has been at the forefront of scientific advancements, collaborating with global pharmaceutical and biotechnology companies to develop innovative solutions that improve drug discovery and development processes.

Charles River Laboratories International Inc is primarily present in the following countries and regions: United States, Canada, Europe, Asia Pacific, and Latin America.

Charles River Laboratories International Inc represents various values and corporate philosophies. The company is committed to their mission of improving the lives of people and animals through innovative research and development. They aim to maintain the highest standards of scientific integrity, ethical conduct, and regulatory compliance. Charles River Laboratories prioritizes collaboration and partnership with their clients to provide comprehensive solutions and exceptional service. With a focus on quality, efficiency, and expertise, they strive to consistently deliver reliable and innovative scientific services and products. Through their dedication to responsible and sustainable practices, Charles River Laboratories aims to make a positive impact on society and the environment.

Analytikere sætter i øjeblikket et gennemsnitligt kursmål på 267,60 USD for Charles River Laboratories International-aktien (median: 273,00 USD), svarende til -13,9 % i forhold til seneste kurs. Konsensus bygger på 23 analytikervurderinger.

Charles River Laboratories International Analytikerens Kursmål 2026

23 analytikere vurderer i øjeblikket Charles River Laboratories International-aktien: 17 anbefaler køb, 6 hold og 0 salg. For 2026 forventer analytikere, at Charles River Laboratories International genererer omsætning på 3,91 Mrd. USD og indtjening pr. aktie på 11,42 USD.

Charles River Laboratories International Analytikerens Kursmål 2026

Omregnet til den aktuelle valutakurs handles Charles River Laboratories International-aktien til 277,24 EUR (310,77 USD).

Charles River Laboratories International-aktien (CRL) er noteret på 6 børser, herunder: NYSE (CRL), SIX (Zürich) (RV6.SW), XETRA (RV6.DE), Frankfurt (RV6.F), München (RV6.MU), Düsseldorf (RV6.DU).

Charles River Laboratories International Inc is a global leader in the field of life sciences, offering its customers a wide range of products and services. The company's business model is based on three main areas: research and development, preclinical services, and bioproducts. Research and Development: Charles River Laboratories offers a variety of services to support its customers in the development of new products. These include chemical and pharmacological screening systems, study design and planning, cell and tissue banking, genotoxicology, protein and antibody production, and much more. Charles River Laboratories has a comprehensive range of scientific and technical capabilities to assist its customers in the development of new drugs, biotechnology products, and medical devices. Preclinical Services: The company provides its customers with a wide range of preclinical services to test the safety and efficacy of products. These services include toxicology, pathology, pharmacology, bioanalytics, and clinical diagnostics. Charles River Laboratories has several preclinical research facilities worldwide and can support customers in the validation of new therapies and products. Bioproducts: Charles River Laboratories produces a variety of bioproducts for research and development, including cell lines, antibodies, nucleic acids, and proteins. The company also offers specialized services such as genetic manipulation and custom modification of cell lines to achieve specific research goals. The company focuses on customer loyalty and has earned the trust of customers by offering high-quality products and services. Charles River Laboratories has a global presence with facilities in North America, Europe, and Asia, and can serve customers worldwide. The company also maintains a strong partnership with the scientific community by supporting research initiatives and public health measures. Charles River Laboratories is committed to offering its customers a comprehensive range of services to meet their needs in the field of life sciences. The company is dedicated to continuously improving its research and development and introducing new services and products to meet the ever-changing needs of customers.

forventet-omsætningen for Charles River Laboratories International er 3,91 Mrd. USD. Dette tal er baseret på aktuelle finansielle data og afspejler virksomhedens forretningsydeevne.

forventet-overskuddet for Charles River Laboratories International er 561,96 Mio. USD. Nettooverskuddet afspejler virksomhedens rentabilitet efter fradrag af alle udgifter.

Pris-til-indtjening-forholdet (P/E) for Charles River Laboratories International er i øjeblikket 27,22. P/E-forholdet sammenligner den nuværende aktiekurs med indtjeningen pr. aktie og hjælper investorer med at vurdere værdiansættelsen af Charles River Laboratories International-aktien.

Pris-til-salgs-forholdet (P/S) for Charles River Laboratories International er i øjeblikket 3,91. P/S-forholdet sammenligner markedskapitalisering med årlig omsætning og fungerer som en værdiansættelsesmetrik for Charles River Laboratories International-aktien.

AlleAktien-kvalitetsscore for Charles River Laboratories International er 3/10.

ISIN for Charles River Laboratories International er US1598641074. ISIN (International Securities Identification Number) er en globalt unik identifikator for værdipapirer.

WKN for Charles River Laboratories International er 939391. WKN (Wertpapierkennnummer) er et seks-cifret tysk identifikationsnummer for værdipapirer.

Tickeren for Charles River Laboratories International er CRL. Tickersymbolet bruges til at handle Charles River Laboratories International-aktier på børsen.